JP7089523B2 - プロバイオティクス組成物およびその使用 - Google Patents

プロバイオティクス組成物およびその使用 Download PDF

Info

Publication number
JP7089523B2
JP7089523B2 JP2019538207A JP2019538207A JP7089523B2 JP 7089523 B2 JP7089523 B2 JP 7089523B2 JP 2019538207 A JP2019538207 A JP 2019538207A JP 2019538207 A JP2019538207 A JP 2019538207A JP 7089523 B2 JP7089523 B2 JP 7089523B2
Authority
JP
Japan
Prior art keywords
cells
probiotic
ttga
treatment
lactobacillus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019538207A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020513780A5 (enExample
JP2020513780A (ja
Inventor
ダニエル アガート
アーレン，イリーニ ラゾウ
ニクラス ラーション，ラーズ
Original Assignee
プロビ アーベー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1700542.2A external-priority patent/GB201700542D0/en
Priority claimed from GBGB1709731.2A external-priority patent/GB201709731D0/en
Application filed by プロビ アーベー filed Critical プロビ アーベー
Publication of JP2020513780A publication Critical patent/JP2020513780A/ja
Publication of JP2020513780A5 publication Critical patent/JP2020513780A5/ja
Application granted granted Critical
Publication of JP7089523B2 publication Critical patent/JP7089523B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2019538207A 2017-01-12 2018-01-12 プロバイオティクス組成物およびその使用 Active JP7089523B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1700542.2 2017-01-12
GBGB1700542.2A GB201700542D0 (en) 2017-01-12 2017-01-12 Probiotic compositions and uses thereof
GBGB1709731.2A GB201709731D0 (en) 2017-06-19 2017-06-19 Probiotic compositions and uses thereof
GB1709731.2 2017-06-19
PCT/EP2018/050789 WO2018130667A1 (en) 2017-01-12 2018-01-12 Probiotic compositions and uses thereof

Publications (3)

Publication Number Publication Date
JP2020513780A JP2020513780A (ja) 2020-05-21
JP2020513780A5 JP2020513780A5 (enExample) 2021-02-25
JP7089523B2 true JP7089523B2 (ja) 2022-06-22

Family

ID=61386800

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019538207A Active JP7089523B2 (ja) 2017-01-12 2018-01-12 プロバイオティクス組成物およびその使用

Country Status (14)

Country Link
US (1) US11166993B2 (enExample)
EP (1) EP3568144B1 (enExample)
JP (1) JP7089523B2 (enExample)
KR (1) KR102500496B1 (enExample)
CN (1) CN110177561B (enExample)
AU (1) AU2018207946B2 (enExample)
BR (1) BR112019014418A2 (enExample)
CA (1) CA3049624A1 (enExample)
CL (1) CL2019001938A1 (enExample)
MX (1) MX2019008292A (enExample)
MY (1) MY195253A (enExample)
PH (1) PH12019501629A1 (enExample)
RU (1) RU2763311C2 (enExample)
WO (1) WO2018130667A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020013439A (es) * 2018-06-18 2021-05-12 Probi Ab Composiciones probioticas y usos de las mismas.
IT201900014550A1 (it) * 2019-08-09 2021-02-09 Abiogen Pharma Spa Uso di colecalciferolo come agente attivo nel trattamento della celiachia
CN116869141A (zh) * 2022-05-05 2023-10-13 内蒙古一康健康发展有限责任公司 一种具有保健功能的益生菌复合物及其制备方法
KR102845919B1 (ko) * 2023-02-28 2025-08-14 주식회사 피엘비앤비 장내 유해세균의 성장 억제 성능이 우수한 한국인 모유 유래 락티카제이바실러스 파라카제이 pl1536 및 이를 유효성분으로 포함하는 기능성식품 조성물
CN119279210A (zh) * 2024-12-16 2025-01-10 山东健源生物科技有限公司 一种复合益生菌发酵含药食同源物质的多谷物后生元制剂及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007108764A2 (en) 2006-03-17 2007-09-27 Probac Ab Thermostable lactobacillus strains
JP2009511470A (ja) 2005-10-06 2009-03-19 プロビ エービー ウイルス感染治療のための乳酸菌の使用
WO2013192163A1 (en) 2012-06-18 2013-12-27 H.J. Heinz Company Gluten-related disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076615A2 (en) * 2003-02-27 2004-09-10 Bioneer A/S Immunomodulating probiotic compounds
WO2006097949A1 (en) * 2005-03-16 2006-09-21 Actial Farmacêutica, Lda. Mixture of at least 6 species of lactic acid bacteria and/or bifidobacteria in the manufacture of sourdough
ZA200802934B (en) * 2005-10-06 2009-09-30 Probi Ab Use of lactobacillus for treatment of virus infections
WO2007108763A1 (en) * 2006-03-17 2007-09-27 Probac Ab Use of lactobacillus strains for promoting immunotolerance in autoimmune disease
PT2367561E (pt) 2008-11-30 2015-10-23 Immusant Inc Composições e métodos para o tratamento da doença celíaca
EP2581461B1 (en) * 2011-10-14 2014-09-24 GenMont Biotech Incorporation Composition and use of lactobacillus paracasei strain GMNL-133 in treating atopic dermatitis or other allergic diseases
AU2014250113B2 (en) * 2013-04-03 2017-03-30 Probi Ab Probiotic strains for use in treatment or prevention of osteoporosis
WO2016083450A2 (en) * 2014-11-25 2016-06-02 Stichting Top Institute Food And Nutrition New probiotic and new biomarker

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009511470A (ja) 2005-10-06 2009-03-19 プロビ エービー ウイルス感染治療のための乳酸菌の使用
JP2009511471A (ja) 2005-10-06 2009-03-19 プロビ エービー 自己免疫疾患治療のための乳酸菌の使用
WO2007108764A2 (en) 2006-03-17 2007-09-27 Probac Ab Thermostable lactobacillus strains
WO2013192163A1 (en) 2012-06-18 2013-12-27 H.J. Heinz Company Gluten-related disorders

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Appl Microbiol Biotechnol，2013年，Vol. 97，pp. 3129-3140
Clinical and Developmental Immunology，2012年，Vol. 2012, Article ID 654143，pp. 1-12
Clinical Microbiology Reviews，2014年，Vol. 27, No. 3，pp. 482-489
Int J Food Sci Nutr，2014年，Vol. 65, No. 8，pp. 953-959

Also Published As

Publication number Publication date
EP3568144C0 (en) 2024-05-08
EP3568144A1 (en) 2019-11-20
MY195253A (en) 2023-01-11
US11166993B2 (en) 2021-11-09
CN110177561B (zh) 2023-09-12
CL2019001938A1 (es) 2019-09-27
CA3049624A1 (en) 2018-07-19
AU2018207946A1 (en) 2019-07-25
PH12019501629A1 (en) 2020-06-01
KR102500496B1 (ko) 2023-02-16
RU2763311C2 (ru) 2021-12-28
EP3568144B1 (en) 2024-05-08
US20190358275A1 (en) 2019-11-28
AU2018207946B2 (en) 2024-07-18
RU2019121145A (ru) 2021-02-12
MX2019008292A (es) 2019-09-16
CN110177561A (zh) 2019-08-27
RU2019121145A3 (enExample) 2021-04-26
BR112019014418A2 (pt) 2020-04-14
WO2018130667A1 (en) 2018-07-19
JP2020513780A (ja) 2020-05-21
KR20190104568A (ko) 2019-09-10

Similar Documents

Publication Publication Date Title
JP7089523B2 (ja) プロバイオティクス組成物およびその使用
JP6182628B2 (ja) 免疫疾患の処置において使用するための、プロバイオティック細菌を含む組成物
Miyazawa et al. Heat-killed Lactobacillus gasseri can enhance immunity in the elderly in a double-blind, placebo-controlled clinical study
Marcial et al. Lactobacillus johnsonii N6. 2 modulates the host immune responses: a double-blind, randomized trial in healthy adults
Braat et al. Lactobacillus rhamnosus induces peripheral hyporesponsiveness in stimulated CD4+ T cells via modulation of dendritic cell function
DK1951272T3 (en) Use of lactobacillus for treatment of virus infections
Kawano et al. Lactobacillus gasseri SBT2055 inhibits adipose tissue inflammation and intestinal permeability in mice fed a high-fat diet
EP4014982B1 (en) Composition for inducing proliferation or accumulation of regulatory t cells
Sugimura et al. Immunomodulatory effect of Lactococcus lactis JCM5805 on human plasmacytoid dendritic cells
WO2012013861A2 (en) Use of blood group status iii
Dargahi et al. Immunomodulatory effects of Streptococcus thermophilus on U937 monocyte cell cultures
Kowalski et al. Celiac Disease—Narrative Review on Progress in Celiac Disease
Feng et al. Species-or genus-dependent immunostimulatory effects of gut-derived potential probiotics
Naito et al. Diverse impact of a probiotic strain, Lacticaseibacillus paracasei Shirota, on peripheral mononuclear phagocytic cells in healthy Japanese office workers: A randomized, double-blind, controlled trial
Talayev et al. Cytokine profile of CCR6+ T-helpers isolated from the blood of patients with peptic ulcer associated with Helicobacter pylori infection
Noorifard et al. Effects of probiotic supplementation on immune response in soldiers: a randomized, double-blinded, placebo-controlled trial
JP2009173548A (ja) 腸内細菌叢改善組成物、アレルギー抑制組成物、およびアレルギー抑制剤
WO2024218197A1 (en) Human milk oligosaccharides
TW202513082A (zh) 漿細胞樣樹狀細胞活化用組成物
Lahcene et al. Characterization of intestinal microbiota in celiac children
Pozo-Rubio et al. Pozo-Rubio T et al. Br J Nutr. 2011 Oct; 106 (8): 1216-23
Omakobia The immunomodulatory effects of probiotics

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220513

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220524

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220610

R150 Certificate of patent or registration of utility model

Ref document number: 7089523

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250